FY2025 Earnings Estimate for OBIO Issued By Chardan Capital

Key Points

• Chardan Capital has revised its FY2025 earnings per share (EPS) estimate for Orchestra BioMed from ($1.69) to ($1.77), maintaining a "Buy" rating with a target price of $20.00.
• In its latest quarterly results, Orchestra BioMed reported an EPS of ($0.50), exceeding analysts' expectations by $0.01, while revenues were reported at $0.84 million.
• Insider David P. Hochman purchased 20,000 shares of Orchestra BioMed stock at an average price of $2.75, reflecting his confidence in the company and increasing his ownership stake by 6.07%.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities research analysts at Chardan Capital cut their FY2025 earnings estimates for Orchestra BioMed in a note issued to investors on Wednesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of ($1.77) per share for the year, down from their prior forecast of ($1.69). Chardan Capital has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.66) per share. Chardan Capital also issued estimates for Orchestra BioMed's FY2026 earnings at ($1.44) EPS.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. The company had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.78 million. Orchestra BioMed had a negative net margin of 2,367.49% and a negative return on equity of 289.42%.

A number of other equities research analysts have also recently weighed in on the company. BTIG Research reiterated a "neutral" rating on shares of Orchestra BioMed in a research note on Wednesday. Barclays reduced their price objective on Orchestra BioMed from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Orchestra BioMed has an average rating of "Buy" and an average target price of $14.00.

Orchestra BioMed Stock Up 2.4%

Orchestra BioMed stock traded up $0.06 during mid-day trading on Monday, hitting $2.55. The company had a trading volume of 188,395 shares, compared to its average volume of 451,225. The stock has a market cap of $98.53 million, a price-to-earnings ratio of -1.39 and a beta of 0.62. Orchestra BioMed has a 1 year low of $2.37 and a 1 year high of $7.04. The company has a quick ratio of 2.09, a current ratio of 2.10 and a debt-to-equity ratio of 48.76. The business has a fifty day moving average of $2.91 and a 200 day moving average of $3.39.

Insider Buying and Selling at Orchestra BioMed

In related news, insider David P. Hochman bought 20,000 shares of the stock in a transaction on Monday, August 4th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $55,000.00. Following the purchase, the insider owned 349,331 shares of the company's stock, valued at $960,660.25. This trade represents a 6.07% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 8.10% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in shares of Orchestra BioMed by 1,137.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 27,922 shares of the company's stock valued at $75,000 after purchasing an additional 25,666 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $67,000. Bank of America Corp DE grew its stake in shares of Orchestra BioMed by 35.7% in the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock valued at $58,000 after purchasing an additional 5,678 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $50,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $118,000. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.